Mouse Monoclonal MSTN Antibody

The myostatin (MSTN) antibody is a therapeutic or research tool targeting myostatin, a protein encoded by the MSTN gene and a member of the TGF-β superfamily. Myostatin acts as a negative regulator of skeletal muscle growth, limiting excessive muscle development by inhibiting myoblast proliferation and differentiation. Discovered in 1997. MSTN gained attention when genetic knockout in animals resulted in dramatic muscle hypertrophy. This sparked interest in modulating myostatin to treat muscle-wasting disorders, such as muscular dystrophy, sarcopenia, or cachexia. MSTN antibodies are designed to bind and neutralize myostatin, blocking its interaction with activin type II receptors (e.g., ActRIIB) and thereby promoting muscle growth. Preclinical studies in animal models demonstrated increased muscle mass and strength, supporting their therapeutic potential. In agriculture, MSTN-inhibiting antibodies have also been explored to enhance livestock muscle yield. However, clinical translation faces challenges: early-phase trials showed mixed efficacy in humans, and safety concerns persist due to myostatin's broader roles in metabolism, fibrosis, and cardiovascular health. Despite setbacks, MSTN antibodies remain a focus in biopharmaceutical development, often combined with other myoregulatory agents. Ongoing research aims to optimize specificity, delivery, and dosing regimens while minimizing off-target effects, balancing therapeutic benefits with systemic risks.